No headlines found.
PRNewswire (Thu, 25-Jun 7:45 AM ET)
PRNewswire (Thu, 11-Jun 7:45 AM ET)
PRNewswire (Tue, 19-May 4:39 PM ET)
PRNewswire (Thu, 14-May 4:32 PM ET)
VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
PRNewswire (Thu, 14-May 4:05 PM ET)
Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026
PRNewswire (Mon, 11-May 8:01 AM ET)
PRNewswire (Tue, 5-May 8:00 AM ET)
Valion Bio Appoints Melinda Lackey as General Counsel
PRNewswire (Mon, 4-May 4:05 PM ET)
VALION BIO BRIEFS PENTAGON LEADERSHIP ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME
PRNewswire (Tue, 28-Apr 8:01 AM ET)
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.
Valion Bio trades on the NASDAQ stock market under the symbol VBIO.
As of July 2, 2026, VBIO stock price declined to $0.50 with 35,425 million shares trading.
VBIO has a market cap of $1.60 million. This is considered a Sub-Micro Cap stock.
VBIO support price is $.47 and resistance is $.56 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VBIO shares will trade within this expected range on the day.
